Eli Lilly on Thursday posted better-than-expected quarterly results, but CVS Health's decision to drop the company's obesity ...

Eli Lilly and Company's stock dropped 11% after CVS's Zepbound exclusion, but analysts see a mispricing opportunity. Click ...

Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

Starting July 1, Wegovy will become the preferred GLP-1 for obesity treatment on CVS Caremark’s largest commercial template ...

New Integration with Gifthealth Simplifies Fulfillment and Medication Visibility for WeightWatchers Clinic MembersNEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- WeightWatchers (NASDAQ: WW) ...

Pharma giant Novo Nordisk is partnering with telehealth companies to expand access to its blockbuster weight loss drug Wegovy ...

WW International shares are trading higher by 79% during Tuesday's session. The company announced a new partnership with Eli ...

This integration allows eligible members to receive on-label prescriptions for Zepbound in a single-dose vial format, particularly benefiting self-pay patients without insurance. Members will also ...

Novo Nordisk and a popular virtual health company are making Wegovy more accessible to millions of more Americans.

The integration will streamline access to Lilly’s FDA-approved Zepbound® (tirzepatide) single-dose vials for WeightWatchers Clinic members with an on-label prescription from their clinician.